Es wäre eine der größten Transaktionen in der Pharmabranche: Der Dax-Konzern Merck will den Krebsarzneientwickler Springworks Therapeutics übernehmen.
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie-Richtlinie
To find out more, including how to control cookies, see here: Cookie-Richtlinie
